CARB-X
Combating Antibiotic-Resistant Bacteria

JULY 2016 - JULY 2021
5 YEARS OF PROGRESS

ADDRESSING THE GLOBAL ANTIBACTERIAL RESISTANCE THREAT

Innovation to prepare for the future

CARB-X accelerates the early development of innovative products to prevent, diagnose and treat serious antibiotic-resistant bacterial infections and promote global health security.

---

**Global Reach**

92 projects funded in 12 countries since launch – $361M in non-dilutive awards.

**Innovative Pipeline**

60 active projects: 19 antibiotics with novel classes, 16 non-traditional therapeutics, 8 vaccines, 4 preventatives (CRISPR phage, microbiome, antibody), and 12 rapid diagnostics.

**Progress of Projects**

9 projects graduated from CARB-X portfolio: 2 secured regulatory approvals, 1 in New Drug Application stage, 1 in Phase 2, and 1 awarded Advanced R&D contract with BARDA. CARB-X has supported 9 projects through IND or IND-equivalent approvals, and 10 projects in Phase 1, of which 8 included First-in-Human activities.

**Funding Rounds**

8 funding rounds, 1163 applications reviewed from 39 different countries.

---

**Portfolio Vision & Strategy**

CARB-X supports the world’s largest, most scientifically diverse antibacterial portfolio and selects projects aligned with an integrated strategy focused on the most serious bacterial threats.

**Expert Wraparound Support**

CARB-X delivers expert support to product developers through its R&D team, global network of 7 accelerators and more than 120 subject matter experts around the world.

**Bacteria Ignore Borders**

CARB-X funds diverse projects including many focused on health challenges in low- and middle-income countries.

**Stewardship & Access**

Each CARB-X-funded project is governed by stewardship and access policies to ensure that, if approved, it is used responsibly and is made accessible to patients who need it.

---

* As of 31 July 2021
The CARB-X Advantage

• Focus on the most serious bacteria in the world
• Select the most promising innovations from around the world to advance the best science
• Provide funding and access to global expert networks to solve specific and cross-portfolio problems and accelerate products towards patients
• Coordinate with other key stakeholders to maximize impact

Trusted Partnership

CARB-X is a non-profit public-private partnership, led by Boston University and dedicated to revitalizing the world’s early development antibacterial pipeline. CARB-X funders are investing up to $480 million from 2016-2022 to support the development of innovative therapeutics, preventatives and rapid diagnostics

CARB-X targets the world’s deadliest antibiotic-resistant pathogens

Numbers in ( ) indicate number of projects* targeting indication

1. LRTI: lower respiratory tract infections eg pneumonia (25)  
2. BSI: bloodstream infections (sepsis) (19)  
3. cUTI: urinary tract infections (18)  
4. cIAI: intra-abdominal infections (8)  
5. STI: sexually transmitted infections (gonorrhea +/- chlamydia) (7)  
6. GI: intestinal microbiome modifying (transplant, cancer, C. difficile infection patients) (5)  
7. CF: cystic fibrosis (5)  
8. ABSSSI: serious skin infections (4)  
10. PJI: prosthetic joint infections (4)  
11. URTI: upper respiratory tract infections (3)

Numbers in ( ) indicate number of projects* that focus on the pathogen. Some projects focus on more than one pathogen

1. K. pneumoniae (37)  
2. E. coli (35)  
3. P. aeruginosa (28)  
4. E. cloacae (28)  
5. A. baumannii (23)  
6. S. aureus (20)  
7. E. faecium (16)  
8. S. pneumoniae (14)  
9. N. gonorrhoeae (10)  
10. S. pyogenes (group A) (11)  
11. Salmonella sp (4)  
12. S. agalactiae (group B) (2)  
13. H. influenzae (2)  
14. C. difficile (1)  
15. Campylobacter sp (1)  
16. Shigella sp (1)  
17. H. pylori (1)  
18. S. agalactiae (2)  
19. E. coli (2)  
20. S. aureus (2)  
21. A. baumannii (2)  
22. P. aeruginosa (2)  
23. E. coli (2)  
24. S. pneumoniae (2)  
25. N. gonorrhoeae (2)  
26. H. influenzae (2)  
27. C. difficile (1)  
28. Campylobacter sp (1)  
29. Shigella sp (1)  
30. H. pylori (1)  
31. E. coli (1)  
32. S. pneumoniae (1)  
33. N. gonorrhoeae (1)  
34. H. pylori (1)  
35. Campylobacter sp (1)  
36. Shigella sp (1)  
37. H. pylori (1)  
38. E. coli (1)  
39. S. pneumoniae (1)  
40. N. gonorrhoeae (1)  
41. H. pylori (1)  
42. Campylobacter sp (1)  
43. Shigella sp (1)  
44. H. pylori (1)  
45. E. coli (1)  
46. S. pneumoniae (1)  
47. N. gonorrhoeae (1)  
48. H. pylori (1)  
49. Campylobacter sp (1)  
50. Shigella sp (1)  
51. H. pylori (1)  
52. E. coli (1)  
53. S. pneumoniae (1)  
54. N. gonorrhoeae (1)  
55. H. pylori (1)  
56. Campylobacter sp (1)  
57. Shigella sp (1)  
58. H. pylori (1)  
59. E. coli (1)  
60. S. pneumoniae (1)  
61. N. gonorrhoeae (1)  
62. H. pylori (1)  
63. Campylobacter sp (1)  
64. Shigella sp (1)  
65. H. pylori (1)  
66. E. coli (1)  
67. S. pneumoniae (1)  
68. N. gonorrhoeae (1)  
69. H. pylori (1)  
70. Campylobacter sp (1)  
71. Shigella sp (1)  
72. H. pylori (1)  
73. E. coli (1)  
74. S. pneumoniae (1)  
75. N. gonorrhoeae (1)  
76. H. pylori (1)  
77. Campylobacter sp (1)  
78. Shigella sp (1)  
79. H. pylori (1)  
80. E. coli (1)  
81. S. pneumoniae (1)  
82. N. gonorrhoeae (1)  
83. H. pylori (1)  
84. Campylobacter sp (1)  
85. Shigella sp (1)  
86. H. pylori (1)  
87. E. coli (1)  
88. S. pneumoniae (1)  
89. N. gonorrhoeae (1)  
90. H. pylori (1)  
91. Campylobacter sp (1)  
92. Shigella sp (1)  
93. H. pylori (1)  
94. E. coli (1)  
95. S. pneumoniae (1)  
96. N. gonorrhoeae (1)  
97. H. pylori (1)  
98. Campylobacter sp (1)  
99. Shigella sp (1)  
100. H. pylori (1)